Stockscreener 앱 받기
16.51
1.32%
-0.22
시간 외 거래:
16.50
-0.01
-0.06%
전일 마감가:
$16.73
열려 있는:
$16.81
하루 거래량:
736.08K
Relative Volume:
0.85
시가총액:
$2.20B
수익:
$298.30M
순이익/손실:
$298.21M
주가수익비율:
7.6304
EPS:
2.1637
순현금흐름:
$166.93M
1주 성능:
-0.84%
1개월 성능:
-2.65%
6개월 성능:
+4.30%
1년 성능:
+42.94%
1일 변동 폭
$16.35
$16.81
1주일 범위
$16.11
$17.30
52주 변동 폭
$11.30
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.51 | 2.20B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Aurinia Pharmaceuticals plots early exit from Montgomery County lease following leadership overhaul - The Business Journals
Aurinia Pharmaceuticals stock heads toward its November 3 report - AD HOC NEWS
Aurinia reports second-quarter profit growth: what it means for Aurinia Pharmaceuticals stock - AD HOC NEWS
Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside (AUPH) - Seeking Alpha
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company - finance.yahoo.com
Tax-withholding stock sale by Aurinia Pharmaceuticals (AUPH) legal chief - Stock Titan
Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH? - StockInvest.us
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
A finance executive who helped launch a lupus drug joins LB Pharmaceuticals - Stock Titan
Is Aurinia Pharmaceuticals (AUPH) Still Below Fair Value After A 60% Rise? - simplywall.st
Kezar Life Sciences stock in focus after Aurinia tender offer and merger terms surface - AD HOC NEWS
Investors - Aurinia Pharmaceuticals Inc.
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)? - Yahoo Finance
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock - Benzinga
ILJIN group pushes Aurinia (NASDAQ: AUPH) stake under 5% after share sales - Stock Titan
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch - webull.com
Aurinia (NASDAQ: AUPH) legal chief sells shares to cover taxes - Stock Titan
Aurinia (AUPH) Quarterly Results: EPS Clears the Reported Estimate at the Close; Market Response: The Share Price Sheds 0.48% in the Available RecordGuidance Update - vinanet.vn
Aurinia (AUPH) Market: Falls 3.59% to $16.65 at the Close; Technical Setup: $15.82 and $17.48 Define the Nearby Reference Levels on the DayBuyback Factor - siam.in
Aurinia (AUPH) Market: Falls 3.59% to $16.65 at the Close; Technical Setup: $15.82 and $17.48 Define the Nearby Reference Levels on the DayTechnical Analysis - vinanet.vn
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Zacks Investment Research
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - finance.yahoo.com
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - TradingView
AUPH Stock Rallies 6% After-Hours — Here’s Why - Stocktwits
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia settles patent dispute with Teva over generic drug By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Australia
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Aurinia settles patent dispute with Teva over generic drug By Investing.com - Investing.com India
Aurinia Settles Patent Litigation with Teva - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Aurinia (AUPH) Latest Price Review: Rises 0.07% to $15.30 in the Current Update; Level Check: the Near-Term Reference Band Stretches From $14.54 to $16.07 under the Current SnapshotETF Outflow Streak - vinanet.vn
Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% UpQuarterly Profit Report - vinanet.vn
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aurinia Pharmaceuticals Inc 주식 (AUPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Robertson Stephen P. | Chief Legal Officer |
Aug 21 '26 |
Sale |
16.97 |
20,975 |
355,946 |
600,787 |
| Stephen P. Robertson | Officer |
Aug 21 '26 |
Proposed Sale |
15.30 |
47,000 |
719,100 |
0 |
| GREGORY KEENAN | Former Affiliate |
Jun 05 '26 |
Proposed Sale |
16.52 |
9,593 |
158,490 |
0 |
| GREGORY KEENAN | Former Affiliate |
Jun 04 '26 |
Proposed Sale |
16.34 |
25,000 |
408,435 |
0 |
| GREGORY KEENAN | Officer |
Jun 02 '26 |
Proposed Sale |
15.39 |
25,000 |
384,750 |
0 |
| TANG KEVIN | Chief Executive Officer |
Jun 02 '26 |
Buy |
15.28 |
206,005 |
3,147,756 |
13,044,106 |
| TANG KEVIN | Chief Executive Officer |
Jun 01 '26 |
Buy |
15.28 |
343,620 |
5,250,520 |
12,838,101 |
| TANG KEVIN | Chief Executive Officer |
May 29 '26 |
Buy |
15.31 |
264,981 |
4,056,951 |
12,494,481 |
| MATTHEW MAXWELL DONLEY | Former Affiliate |
May 11 '26 |
Proposed Sale |
15.84 |
717,688 |
11,368,178 |
0 |
| JOSEPH MILLER | Former Affiliate |
May 11 '26 |
Proposed Sale |
15.84 |
500,503 |
7,927,968 |
0 |
0.84%
0.34%
자본화:
|
볼륨(24시간):